Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 01:14 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Efficacy of Letrozole in Recurrent Ovarian Cancer
NCT04421547 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · PHASE3 · terminated · last registry update 2025-03-07 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Logistical problems impacting the speed of enrolment” | – | Registry record, Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CYP19A1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-02-24Results posted on the registry: Mayo Clinic, Anastrozole + Denifanstat (NCT03179904)
- 2026-02-24Also stopped (terminated): Sanofi, Amcenestrant + Fulvestrant (NCT04059484)
- 2026-02-24Results posted on the registry: City of Hope Medical Center, Fulvestrant + Letrozole (NCT02778685)
- 2026-02-12Results posted on the registry: Alliance Foundation Trials, LLC., palbociclib + trastuzumab (NCT02947685)
- 2026-02-12Also stopped (withdrawn): Danish Breast Cancer Cooperative Group, Trastuzumab deruxtecan (T-DXd) + Ribociclib with ET (NCT06585969)
- 2026-02-10Phase 3 first posted: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Ribociclib plus aromatase inhibitor + Aromatase inhibitor (NCT07400523)
- 2026-02-06Phase 3 first posted: National Cancer Institute (NCI), Anastrozole + Chemotherapy (NCT07391774)
- 2026-01-28Results posted on the registry: University of California, San Francisco, Placebo oral tablet + Letrozole (NCT04002141)
- 2026-01-21Results posted on the registry: University of Chicago, Docetaxel + Herceptin (NCT03879577)
- 2026-01-16Phase 3 first posted: Shandong Suncadia Medicine Co., Ltd., HRS-8080 Tablets + Letrozole tablets (NCT07349069)
- 2026-01-14Phase 3 first posted: Rovi Pharmaceuticals Laboratories, Letrozole SIE + Ribociclib + Oral placebo + Oral Femara® + Ribociclib + Injectable placebo (NCT07340658)
- 2026-01-06Phase 3 first posted: Fudan University, PD1 antibody + Medroxyprogesterone Acetate 500 MG (NCT07319429)
- 2025-12-23Results posted on the registry: Gynecologic Oncology Group, Ribociclib + Letrozole (NCT03673124)
- 2025-12-22Phase 3 first posted: Peking Union Medical College Hospital, Western Medicine + Traditional Chinese Medicine (NCT07296614)
- 2025-12-18Also stopped (terminated): Mario Negri Institute for Pharmacological Research, all-trans retinoic acid + Anastrozole 1mg (NCT04113863)
- 2025-12-15Also stopped (terminated): Fudan University, Letrozole 2.5mg (NCT05454358)
- 2025-12-09Results posted on the registry: Memorial Sloan Kettering Cancer Center, Vagifem® (vaginal 17β-estradiol) questionnaire & menopause symptom checklist (NCT00984399)
- 2025-11-10Results posted on the registry: Hoffmann-La Roche, Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody + Bevacizumab (NCT03280563)
- 2025-10-22Results posted on the registry: Shayna Showalter, MD, tamoxifen, letrozole, anastrozole, or exemestane (NCT04272801)
- 2025-09-24Phase 3 first posted: Japanese Foundation for Cancer Research, Endocrine therapy + Abemaciclib + Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen (NCT07190443)
- 2025-09-18Also stopped (terminated): Sanofi, Amcenestrant (SAR439859) + Letrozole (NCT04191382)
- 2025-09-15Phase 3 first posted: Eli Lilly and Company, LY4064809 + Placebo (NCT07174336)
- 2025-09-11Also stopped (terminated): Sanofi, Amcenestrant-matching placebo + SAR439859 (NCT04478266)
- 2025-09-04Phase 3 first posted: Fudan University, Endocrine Therapy of Physician's Choice (NCT07153757)
- 2025-08-29Results posted on the registry: Arvinas Inc., ARV-471 + Anastrozole (NCT05549505)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision